Japer Therapeutics Warrants
JSPRW
8 hedge funds and large institutions have $121K invested in Japer Therapeutics Warrants in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 2.17% → 2.17% (-0%)
20% less funds holding
Funds holding: 10 → 8 (-2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
65% less capital invested
Capital invested by funds: $345K → $121K (-$224K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$7.56K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
-$4.13K |
| 2 |
ICM
Ionic Capital Management
New York
|
-$2.24K |
| 3 |
Walleye Capital
New York
|
-$26 |
| 4 |
Morgan Stanley
New York
|
-$12 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAC
1
Cowen and Company
New York
| $43.5K | +$7.56K | +88,015 | +11% |
|
|
2
Walleye Capital
New York
| $35K | -$26 | -301 | -0% |
|
|
ICM
3
Ionic Capital Management
New York
| $20.9K | -$2.24K | -26,079 | -6% |
|
|
TCM
4
Tenor Capital Management
New York
| $12.5K | – | – | – |
|
|
CL
5
CSS LLC
Chicago,
Illinois
| $4.1K | – | – | – |
|
|
ZA
6
Zazove Associates
Incline Village,
Nevada
| $4K | – | – | – |
|
7
Walleye Trading
New York
| $705 | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $2 | +$3 | +37 | New |
|
|
EPM
9
Equitec Proprietary Markets
Chicago,
Illinois
| – | -$4.13K | -33,586 | Closed |
|
|
10
Morgan Stanley
New York
| – | -$12 | -100 | Closed |
|
|
11
Osaic Holdings
Scottsdale,
Arizona
| – | -$5 | -50 | Closed |
|
JSPRW Hedge Fund Activity: Q3 2023 in Review
8 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q3 2023, worth a combined $121K — down 65% from $345K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of JSPRW and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Cowen and Company, adding an estimated $7.56K. The largest seller was Equitec Proprietary Markets, exiting entirely with an estimated $4.13K sold.
- 8 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q3 2023, down from 10 in Q2 2023.
- Funds reported $121K of Japer Therapeutics Warrants stock for Q3 2023, down 65% quarter-over-quarter.
- 1 fund opened new Japer Therapeutics Warrants positions in Q3 2023 and 3 closed out, a net change of -2 holders.
- The largest Japer Therapeutics Warrants buyer in Q3 2023 was Cowen and Company, an estimated $7.56K added.
- The largest Japer Therapeutics Warrants seller in Q3 2023 was Equitec Proprietary Markets, an estimated $4.13K sold.
Based on aggregated 13F filings for Q3 2023.